Effect of MMX^® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials

References

• Bernstein CN Wajda A Svenson LW The epidemiology of inflammatory bowel disease in Canada: a population-based study Am J Gastroenterol 2006 101 7 1559 1568 16863561
   PubMed Web of Science ®Google Scholar
• Loftus CG Loftus EVJr Harmsen WS Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000 Inflamm Bowel Dis 2007 13 3 254 261 17206702
   PubMed Web of Science ®Google Scholar
• Cosnes J Gower-Rousseau C Seksik P Cortot A Epidemiology and natural history of inflammatory bowel diseases Gastroenterology 2011 140 6 1785 1794 21530745
   PubMed Web of Science ®Google Scholar
• Kornbluth A Sachar DB Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee Am J Gastroenterol 2010 105 3 501 523 20068560
   PubMed Web of Science ®Google Scholar
• D’Haens G Sandborn WJ Barrett K Hodgson I Streck P Once daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis Am J Gastroenterol 2012 107 7 1064 1077 22565161
   PubMed Web of Science ®Google Scholar
• Kane S Katz S Jamal MM Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis Inflamm Bowel Dis 2012 18 6 1026 1033 21837775
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR Kamm MA Sandborn WJ Lyne A Joseph RE MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations Aliment Pharmacol Ther 2008 27 11 1094 1102 18363894
   PubMed Web of Science ®Google Scholar
• Sandborn WJ Kamm MA Lichtenstein GR Lyne A Butler T Joseph RE MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials Aliment Pharmacol Ther 2007 26 2 205 215 17593066
   PubMed Web of Science ®Google Scholar
• Longobardi T Walker JR Graff LA Bernstein CN Health service utilization in IBD: comparison of self-report and administrative data BMC Health Serv Res 2011 11 137 21627808
   PubMed Web of Science ®Google Scholar
• Brook I Frazier EH Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis J Med Microbiol 2000 49 9 827 830 10966232
   PubMed Web of Science ®Google Scholar
• Brandimarte G Tursi A Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease Med Sci Monit 2004 10 5 I70 I73
   Web of Science ®Google Scholar
• Comparato G Fanigliulo L Cavallaro LG Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up Dig Dis Sci 2007 52 11 2934 2941 17410435
   PubMed Web of Science ®Google Scholar
• Di Mario F Aragona G Leandro G Efficacy of mesalazine in the treatment of symptomatic diverticular disease Dig Dis Sci 2005 50 3 581 586 15810646
   PubMed Web of Science ®Google Scholar
• Tursi A Brandimarte G Giorgetti G Elisei W Maiorano M Aiello F The clinical picture of uncomplicated versus complicated diverticulitis of the colon Dig Dis Sci 2008 53 9 2474 2479 18231855
   PubMed Web of Science ®Google Scholar
• Trepsi E Colla C Panizza P Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results Minerva Gastroenterol Dietol 1999 45 4 245 252 Italian 16498335
   PubMedGoogle Scholar
• Tursi A Brandimarte G Giorgetti GM Elisei W Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon Dig Dis Sci 2007 52 3 671 674 17253134
   PubMed Web of Science ®Google Scholar
• Shire Development LLC Prevention of Recurrence of Diverticulitis (PREVENT1) Available from: http://www.clinicaltrials.gov/ct2/show/NCT00545740. NLM identifier: NCT00545740 Accessed February 1, 2013
   Google Scholar
• Shire Development LLC Prevention of Recurrence of Diverticulitis (PREVENT2) Available from: http://www.clinicaltrials.gov/ct2/show/NCT00545103?term=NCT00545103&rank=1. NLM identifier: NCT00545103 Accessed February 1, 2013
   Google Scholar
• Jacobs DO Clinical practice. Diverticulitis N Engl J Med 2007 357 20 2057 2066 18003962
   PubMed Web of Science ®Google Scholar
• Szojda MM Cuesta MA Mulder CM Felt-Bersma RJ Review article: management of diverticulitis Aliment Pharmacol Ther 2007 26 Suppl 2 67 76 18081651
   PubMed Web of Science ®Google Scholar
• Schechter S Mulvey J Eisenstat TE Management of uncomplicated acute diverticulitis: results of a survey Dis Colon Rectum 1999 42 4 470 475 10215046
   PubMed Web of Science ®Google Scholar
• Sjovall J Alvan G Huitfeldt B Intra- and inter-individual variation in pharmacokinetics of intravenously infused amoxycillin and ampicillin to elderly volunteers Br J Clin Pharmacol 1986 21 2 171 181 3954933
   PubMed Web of Science ®Google Scholar
• Washington C Hou SY Hughes NC Campanella C Berner B Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics J Clin Pharmacol 2007 47 10 1320 1326 17724088
   PubMed Web of Science ®Google Scholar
• Dilger K Fux R Rock D Morike K Gleiter CH Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study J Clin Pharmacol 2007 47 12 1532 1539 18048573
   PubMed Web of Science ®Google Scholar
• Pokrajac M Miljković B Simić D Brzaković B Galetin A Comparative pharmacokinetics and bioavailability of two cotrimoxazole preparations Pharmazie 1998 53 7 470 472 9699223
   PubMed Web of Science ®Google Scholar
• Sheikh SM Alkaysi HN Gharaibeh AM Amari FF Sallam E Shubair MS Analysis and bioequivalency study on two tablet formulations of co-trimoxazole J Clin Pharm Ther 1993 18 2 109 114 8458878
   PubMed Web of Science ®Google Scholar
• LIALDA^® (mesalamine) delayed-release tablets, for oral use [package insert] Wayne, PA Shire US Inc. 2011
   Google Scholar
• Ricart E Taylor WR Loftus EV N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis Am J Gastroenterol 2002 97 7 1763 1768 12135032
   PubMed Web of Science ®Google Scholar
• Pearce RE Cohen-Wolkowiez M Sampson MR Kearns GL The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst Drug Metab Dispos 2013 41 9 1686 1694 23813797
   PubMed Web of Science ®Google Scholar
• Cantilena LR Katki AG Klecker RW Collins JM Metabolism by N-acetyltransferase 1 in vitro and in healthy volunteers: a prototype for targeted inhibition J Clin Pharmacol 2004 44 12 1405 1411 15545312
   PubMed Web of Science ®Google Scholar
• Cribb AE Nakamura H Grant DM Miller MA Spielberg SP Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism Biochem Pharmacol 1993 45 6 1277 1282 8466547
   PubMed Web of Science ®Google Scholar
• Sweetman S Martindale: the complete drug reference – online via MedicinesComplete London, UK Pharmaceutical Press Available from: http://www.pharmpress.com/product/MC_MART/martindale/sulfamethoxazole Accessed February 8, 2014
   Google Scholar
• Kim I Apriso Drug Approval Package: Clinical Pharmacology and Biopharmaceutics Review Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022301s000_ClinPharmR.pdf
   Google Scholar
• Klotz U Maier KE Pharmacology and pharmacokinetics of 5-aminosalicylic acid Dig Dis Sci 1987 32 Suppl 12 46S 50S 3319458
   PubMed Web of Science ®Google Scholar
• Brogden RN Sorkin EM Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease Drugs 1989 38 4 500 523 2684592
   PubMed Web of Science ®Google Scholar
• ICH [homepage on Internet) Efficacy Single: Good Clinical Practice Available from: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/good-clinical-practice.html Accessed March 5, 2014
   Google Scholar
• Shire Development LLC Amoxicillin Drug Interaction Study With MMX^® Mesalazine/Mesalamine Available from: http://clinicaltrials.gov/ct2/show/NCT01442688. NLM identifier: NCT01442688 Accessed March 5, 2014
   Google Scholar
• Shire Development LLC Ciprofloxacin XR Drug Interaction Study With MMX^® Mesalazine/Mesalamine Available from: http://clinicaltrials.gov/ct2/show/NCT01402947. NLM identifier: NCT01402947 Accessed March 5, 2014
   Google Scholar
• Shire Development LLC Metronidazole Drug Interaction Study With MMX^® Mesalazine/Mesalamine Available from: http://clinicaltrials.gov/ct2/show/NCT01418365. NLM identifier: NCT01418365 Accessed March 5, 2014
   Google Scholar
• Shire Development LLC Sulfamethoxazole Drug Interaction Study With MMX^® Mesalazine/Mesalamine Available from: http://clinicaltrials-lhc.nlm.nih.gov/ct2/show/NCT01469637?term=NCT01469637&rank=1. NLM identifier: NCT01469637 Accessed September 26, 2012
   Google Scholar
• Sailer R Arnold P Erenmemisoglu A Comparative pharmacokinetics of two tablet formulations of amoxicillin: bioequivalence assessment Arzneimittelforschung 2007 57 4 227 231 17515293
   PubMed Web of Science ®Google Scholar
• Idkaidek NM Al-Ghazawi A Najib NM Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach Biopharm Drug Dispos 2004 25 9 367 372 15495146
   PubMed Web of Science ®Google Scholar
• Hassan Y Alfadly SO Azmin MN Bioequivalence evaluation of two different formulations of ciprofloxacin tablets in healthy volunteers Singapore Med J 2007 48 9 819 823 17728962
   PubMedGoogle Scholar
• Cuadrado A Gascon AR Solinis MA Bioequivalence of two oral ciprofloxacin tablets formulations Int J Clin Pharmacol Ther 2004 42 6 336 341 15222727
   PubMed Web of Science ®Google Scholar
• Gatchev E Brater M de MC Bioequivalence of a novel oral metronidazole formulation Arzneimittelforschung 2006 56 8 612 616 17009844
   PubMed Web of Science ®Google Scholar
• Alonso CR Bernardo ER Del Cisne Valle Alvarez D Bioequivalence of two commercial preparations of trimethoprim/sulfamethoxazole: a randomized, single-dose, single-blind, crossover trial Clin Ther 2007 29 2 326 333 17472824
   PubMed Web of Science ®Google Scholar
• Del Tacca M Pasqualetti G Di PA Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers Br J Clin Pharmacol 2009 68 1 34 42 19660001
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation Silver Spring, MD US Food and Drug Administration Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf Accessed February 8, 2014
   Google Scholar
• US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research Guidance For Industry: Bioavailability And Bioequivalence Studies For Orally Administered Drug Products – General Considerations Silver Spring, MD US Food and Drug Administration Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070124.pdf Accessed December 5, 2012
   Google Scholar
• Fast DM Kelley M Viswanathan CT Workshop report and follow-up – AAPS Workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples – implications of Crystal City recommendations AAPS J 2009 11 2 238 241 19381839
   PubMedGoogle Scholar
• Alonso Campero R Bernardo Alvarez D González de la Parra M Namur Montalvo S Burke Fraga V Silva Hernandez R De Lago Acosta A Bioequivalence of two commercial preparations of trimethoprim/sulfamethoxazole: a randomized, single-dose, single-blind, crossover trial Clin Ther 2007 29 2 326 333 17472824
   PubMed Web of Science ®Google Scholar
• Baglie S Rosalen PL Franco LM Comparative bioavailability of 875 mg amoxicillin tablets in healthy human volunteers Int J Clin Pharmacol Ther 2005 43 7 350 354 16035378
   PubMed Web of Science ®Google Scholar
• Mainz D Borner K Koeppe P Kotwas J Lode H Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration J Antimicrob Chemother 2002 50 5 699 706 12407126
   PubMed Web of Science ®Google Scholar
• Todd PA Benfield P Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use Drugs 1990 39 2 264 307 2184003
   PubMed Web of Science ®Google Scholar
• Sweetman S Martindale: the complete drug reference – online via MedicinesComplete London, UK Pharmaceutical Press Available from: http://www.pharmpress.com/product/MC_MART/martindale/amoxicillin Accessed January 24, 2013
   Google Scholar
• Sweetman S Martindale: the complete drug reference – online via MedicinesComplete London, UK Pharmaceutical Press Available from: http://www.pharmpress.com/product/MC_MART/martindale/ciprofloxacin Accessed January 24, 2013
   Google Scholar
• Aminimanizani A Beringer P Jelliffe R Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials Clin Pharmacokinet 2001 40 3 169 187 11327197
   PubMed Web of Science ®Google Scholar
• Vance-Bryan K Guay DR Rotschafer JC Clinical pharmacokinetics of ciprofloxacin Clin Pharmacokinet 1990 19 6 434 461 2292168
   PubMed Web of Science ®Google Scholar
• Lau AH Lam NP Piscitelli SC Wilkes L Danziger LH Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives Clin Pharmacokinet 1992 23 5 328 364 1478003
   PubMed Web of Science ®Google Scholar
• Van der Ven AJ Mantel MA Vree TB Koopmans PP Van der Meer JW Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole Br J Clin Pharmacol 1994 38 2 147 150 7981016
   PubMed Web of Science ®Google Scholar